Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver.
BACKGROUND
Several antipsychotic drugs (APDs) have high propensity to induce weight gain and dyslipidemia in patients, with clozapine and olanzapine as the most potent drugs. These lipid-related effects have been attributed to drug-mediated blockade or antagonism of histamine H1 and serotonin 5-HT2 receptors as well as activation of hypothalamic AMP-activated protein kinase. We recently showed that APDs activate lipid biosynthesis in cultured liver cells through stimulation of the sterol regulatory element-binding protein (SREBP) transcription factors.


OBJECTIVE
The objective of the study was to search for clozapine-related lipogenic effects in peripheral tissues in vivo using rat liver as target organ.


METHODS
Adult female Sprague-Dawley rats were administered single intraperitoneal injections of clozapine (25 and 50 mg/kg). Hepatic lipid levels were measured during a 48-h time course. Real-time quantitative PCR was used to analyze expression of genes involved in lipid biosynthesis, oxidation, efflux, and lipolysis.


RESULTS
We identified an initial up-regulation of central lipogenic SREBP target genes, followed by a marked and sustained down-regulation. We also observed a sequential transcriptional response for fatty acid beta-oxidation and cholesterol efflux genes, normally controlled by the peroxisome proliferator activated receptor alpha and liver X receptor alpha transcription factors, and also down-regulation of genes encoding major lipases. The transcriptional responses were associated with a significant accumulation of triacylglycerol, phospholipids, and cholesterol in the liver.


CONCLUSIONS
These results demonstrate that acute clozapine exposure affects SREBP-regulated lipid biosynthesis as well as other lipid homeostasis pathways. We suggest that such drug-induced effects on lipid metabolism in peripheral tissues are relevant for the metabolic adverse effects associated with clozapine and possibly other APDs.
Fernø
Johan
J
Department of Clinical Medicine, Dr. Einar Martens' Research Group for Biological Psychiatry and Bergen Mental Health, Research Center, University of Bergen, Bergen, Norway. johan.ferno@uib.no
Vik-Mo
Audun O
AO
Jassim
Goran
G
Håvik
Bjarte
B
Berge
Kjetil
K
Skrede
Silje
S
Gudbrandsen
Oddrun A
OA
Waage
Jo
J
Lunder
Niclas
N
Mørk
Sverre
S
Berge
Rolf K
RK
Jørgensen
Hugo A
HA
Steen
Vidar M
VM
D000818:Animals; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000633:toxicity*; D002788:Cholesterol Esters / Q000378:metabolism; D003024:Clozapine / Q000008:administration & dosage / Q000633:toxicity*; D004268:DNA-Binding Proteins / Q000378:metabolism*; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects*; D007274:Injections, Intraperitoneal; D008049:Lipase / Q000235:genetics; D050356:Lipid Metabolism / Q000187:drug effects* / Q000235:genetics; D008099:Liver / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D000071518:Liver X Receptors; D008297:Male; D057093:Orphan Nuclear Receptors; D047493:PPAR alpha / Q000378:metabolism*; D010743:Phospholipids / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism*; D051780:Sterol Regulatory Element Binding Protein 1 / Q000378:metabolism*; D013997:Time Factors; D014280:Triglycerides / Q000378:metabolism
D014150:Antipsychotic Agents; D002788:Cholesterol Esters; D004268:DNA-Binding Proteins; D000071518:Liver X Receptors; C000605215:Nr1h3 protein, rat; D057093:Orphan Nuclear Receptors; D047493:PPAR alpha; D010743:Phospholipids; D018160:Receptors, Cytoplasmic and Nuclear; C497389:Srebf1 protein, rat; D051780:Sterol Regulatory Element Binding Protein 1; D014280:Triglycerides; D008049:Lipase; D003024:Clozapine